BMEZ:NYE-BlackRock Health Sciences Trust II (USD)

COMMON STOCK | |

Last Closing

USD 15.89

Change

+0.13 (+0.82)%

Market Cap

USD 1.64B

Volume

0.22M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Address: 50 Hudson Yards, New York, NY, United States, 10001

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TBB AT&T Inc

-0.06 (-0.24%)

USD 151.65B
PRS Prudential Financial Inc

-0.13 (-0.52%)

USD 44.13B
ALL-PB The Allstate Corporation

-0.03 (-0.12%)

USD 33.24B
SOJC Southern Co

-0.14 (-0.56%)

USD 24.92B
AIZN Assurant Inc

-0.08 (-0.36%)

USD 9.38B
RZB Reinsurance Group of America I..

+0.02 (+0.08%)

USD 8.88B
PCG-PA Pacific Gas and Electric Compa..

-0.38 (-1.50%)

USD 6.63B
PCG-PB Pacific Gas and Electric Compa..

+0.10 (+0.44%)

USD 6.02B
UNMA Unum Group

-0.03 (-0.12%)

USD 5.74B
PCG-PD Pacific Gas and Electric Compa..

+0.03 (+0.16%)

USD 5.44B

ETFs Containing BMEZ

PCEF Invesco CEF Income Compos.. 3.07 % 0.50 %

+0.06 (+0.16%)

USD 0.81B
YYY Amplify High Income ETF 2.97 % 0.50 %

+0.02 (+0.16%)

USD 0.52B

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.46% N/A N/A 51% F
Dividend Return 9.12% N/A N/A 96% N/A
Total Return 17.59% N/A N/A 69% C-
Trailing 12 Months  
Capital Gain 12.94% N/A N/A 40% F
Dividend Return 10.82% N/A N/A 93% A
Total Return 23.76% N/A N/A 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.44% N/A N/A 12% F
Dividend Return -0.12% N/A N/A 23% F
Total Return 6.32% N/A N/A 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 24.33% N/A N/A 43% F
Risk Adjusted Return -0.51% N/A N/A 24% F
Market Capitalization 1.64B N/A N/A 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike